Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00300430 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,911
- Enrollment target
NCT00300430: Completed Phase 3 study, sponsored by Abbott.
NCT00300430 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 1,911 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (148% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00300430, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,911 participants
- Enrollment target
Study Summary
The primary purpose of this study is to test the safety and the effects of using an investigational drug regimen; once daily ABT-335 (Investigational drug) administered in combination with once daily atorvastatin calcium, rosuvastatin calcium or simvastatin in patients with abnormal lipid levels in the blood.
Interventions
- DRUG ABT-335 and rosuvastatin calcium
- DRUG ABT-335 and atorvastatin calcium
- DRUG ABT-335 and simvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,911 participants |
| Start Date | 2006-09 |
| Phase | Phase 3 |
What the finished NCT00300430 record still lists
NCT00300430 is an interventional study that assigns participants to a tested intervention. Its 1,911 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (148% higher).
The record links to 0 conditions, and to 3 interventions - of which ABT-335 and rosuvastatin calcium is the first listed.
NCT00300430 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00300430 about?
NCT00300430 is a clinical study titled "Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.". The primary purpose of this study is to test the safety and the effects of using an investigational drug regimen; once daily ABT-335 (Investigational drug) administered in combination with once daily atorvastatin calcium, rosuvastatin calcium or simvastatin in patients with abnormal lipid levels in ...
What is the current status of trial NCT00300430?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,911 participants. The study started on 2006-09.
What interventions are being tested in trial NCT00300430?
The interventions under investigation include: ABT-335 and rosuvastatin calcium (DRUG), ABT-335 and atorvastatin calcium (DRUG), ABT-335 and simvastatin (DRUG).
Who is sponsoring clinical trial NCT00300430?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00300430's enrollment target sits among peer trials
1,911 109th of 2000 higher than 1,892 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05174169 · 1,912 participants · Phase 2
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
- NCT06799117 · 1,912 participants · NA
Adaptive Decision Support for Addiction Treatment Master
- NCT06058455 · 1,920 participants · NA
An Evaluation of an Online Sexual Assault Resistance Program (IDEA3)
- NCT03729180 · 1,900 participants · NA
The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia